Gloomy outlook for FY21; R&D setbacks worrisome
19/02/21 -"Along the near-to mid-term headwinds — pandemic-related disruptions and rising competition — the dividend cut from FY22 onwards is also a cause of worry. Thus, we trim our target price by 11%."
Pages
67
Language
English
Published on
19/02/21
You may also be interested by these reports :
25/02/21
Bayer really needs a kind of breakthrough or a brilliant idea to change the sentiment on the name. We understand glyphosate-related issues and the ...
24/02/21
FY20 sales and operating profit targets were exceeded, led by higher Darzalex royalties and lower R&D costs. Given its convenience dosing, Darzalex ...
19/02/21
Along the near-to mid-term headwinds — pandemic-related disruptions and rising competition — the dividend cut from FY22 onwards is also a cause of ...
15/02/21
Benefiting from the resilience of the oncology franchisee, sales momentum accelerated in Q4 and the FY20 targets were exceeded. Assuming the phased ...